A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

NCT05945901 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

669

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
DRUG: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab

Sponsor

Jiangsu HengRui Medicine Co., Ltd.